Helle Brander Eriksen

Helle Brander Eriksen

Auto-generated profile, based on publicly available information

Helle Brander Eriksen

Department of Clinical Microbiology, Herlev and Gentofte Hospital, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SBSofie Biering-Sørensen
Sofie Biering-Sørensen
PAPeter Aaby
Peter Aaby
NLNajaaraq Lund
Najaaraq Lund
IMIvan Monteiro
Ivan Monteiro
KJKristoffer Jarlov Jensen
Kristoffer Jarlov Jensen
CBChristine Stabell Benn
Christine Stabell Benn
BCG vaccine may reduce overall mortality by increasing resistance to nontuberculosis infections. In 2 randomized trials in Guinea-Bissau of early BCG-Denmark (Statens Serum Institut) given to low-weight (LW) neonates (<2500 g at inclusion) to reduce infant mortality rates, we observed a very beneficial effect in the neonatal period. We therefore conducted the present trial to test whether early BCG-Denmark reduces neonatal mortality by 45%. We also conducted a meta-analysis of the 3 BCG-Denmark trials. In 2008–2013, we randomized LW neonates to “early BCG-Denmark” (intervention group; n = 2083) or “control” (local policy for LW and no BCG-Denmark; n = 2089) at discharge from the maternity ward or at first contact with the health center. The infants were randomized (1:1) without blinding in blocks of 24. Data was analyzed in Cox hazards models providing mortality rate ratios (MRRs). We had prespecified an analysis censoring follow-up at oral poliovirus vaccine campaigns. Early administration of BCG-Denmark was associated with a nonsignificant reduction in neonatal mortality rate (MRR, 0.70; 95% confidence interval [CI], .47–1.04) and a 34% reduction (0.66; .44–1.00) when censoring for oral poliovirus vaccine campaigns. There was no reduction in mortality rate for noninfectious diseases, but a 43% reduction in infectious disease mortality rate (MRR, 0.57; 95% CI, .35–.93). A meta-analysis of 3 BCG trials showed that early BCG-Denmark reduced mortality by 38% (MRR, 0.62; 95% CI, .46–.83) within the neonatal period and 16% (0.84; .71–1.00) by age 12 months. Early administration of BCG-Denmark in LW infants is associated with major reductions in mortality rate. It is important that all LW infants receive early BCG in areas with high neonatal mortality rates. NCT00625482.

9 September 2014 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KJKristoffer Jarlov Jensen
Kristoffer Jarlov Jensen
NLNanna Larsen
Nanna Larsen
SBSofie Biering-Sørensen
Sofie Biering-Sørensen
AAAndreas Andersen
Andreas Andersen
HEHelle Brander Eriksen
Helle Brander Eriksen
CBChristine Stabell Benn
Christine Stabell Benn
Background. Bacillus Calmette–Guérin (BCG) seems to have beneficial nonspecific effects; early BCG vaccination of low-birth-weight (LBW) newborns reduces neonatal mortality by >40% due to prevention of primarily septicemia and pneumonia. Methods. Within a randomized trial in LBW infants in Guinea-Bissau of early BCG vs the usual postponed BCG, a subgroup was bled 4 weeks after randomization. Levels of interleukin (IL)-1β, IL-5, IL-6, IL-10, IL-17, interferon (IFN)-γ and tumor necrosis factor (TNF)-α were measured from whole-blood assays stimulated with innate agonists to Toll-like receptor (TLR)-2, -4 or -7/8, or purified protein derivative (PPD). Results. Among 467 infants, BCG significantly increased the in vitro cytokine responses to purified protein derivative of Mycobacterium tuberculosis (PPD), as expected. BCG was also associated with increased responses to heterologous innate stimulation, particularly of the cytokines IL-1β, IL-6, TNF-α, and IFN-γ. Conclusion. Four weeks after immunization, BCG-vaccinated infants have a significantly increased production of cytokines upon heterologous challenge, particularly T helper cell type 1 polarizing and typically monocyte-derived pro-inflammatory cytokines. BCG may accelerate the development of the neonatal immune system, mediating comprehensive protection against infections and mortality.

1 February 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
HEHelle Brander Eriksen
Helle Brander Eriksen
HGHeidi Gumpert
Heidi Gumpert
CFCecilie Haase Faurholt
Cecilie Haase Faurholt
HWHenrik Westh
Henrik Westh
In a hospital-acquired infection with multidrug-resistant Elizabethkingia, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and 16S rRNA gene analysis identified the pathogen as Elizabethkingia miricola. Whole-genome sequencing, genus-level core genome analysis, and in silico DNA-DNA hybridization of 35 Elizabethkingia strains indicated that the species taxonomy should be further explored.

1 October 2014 in Vaccine
Verified
Journal Article
Open access
KJKristoffer Jarlov Jensen
Kristoffer Jarlov Jensen
HKHanne Sophie Karkov
Hanne Sophie Karkov
NLNajaaraq Lund
Najaaraq Lund
AAAndreas Andersen
Andreas Andersen
HEHelle Brander Eriksen
Helle Brander Eriksen
CBChristine Stabell Benn
Christine Stabell Benn
Vaccines may have non-specific effects. An observational study from Guinea-Bissau suggested that oral polio vaccine at birth (OPV0) provided with Bacillus Calmette-Guérin (BCG) vaccine was associated with down-regulation of the immune response to BCG vaccine 6 weeks later. Based on the previous finding, we wanted to test our a priori hypothesis that OPV would dampen the immune response to BCG, and secondarily to test immune responses to other antigens. The study was conducted at the Bandim Health Project in Guinea-Bissau in 2009-2010. Infants were randomised to OPV0+BCG versus BCG alone at birth, and subsequently randomised to have a blood sample taken at 2, 4 or 6 weeks post-randomisation. Excreted levels of cytokines (IL-2, IL-5, IL-10, TNF-α and IFN-γ) were measured from whole blood in vitro stimulations with a panel of recall vaccine antigens (BCG, PPD, OPV), mitogen (PHA) or innate agonists (LPS, Pam3cys, PolyI:C). Additionally, we measured the local reaction to BCG, white blood cell distribution, C-reactive protein (CRP) and retinol-binding protein (RBP). Cytokine production was analysed as the prevalence ratios of responders above the median. Blood samples from 430 infants (209 OPV0+BCG; 221 BCG alone) were analysed. There were no strong differences in effects 2, 4 and 6 weeks post-randomisation and subsequent analyses were performed on the pooled data. As hypothesised, receiving OPV0+BCG versus BCG alone was associated with significantly lower prevalence of IFN-γ responses to PPD (prevalence ratio (PR): 0.84 (0.72-0.98)) and reduced IL-5 to PPD (PR: 0.78 (0.64-0.96)). No effects were observed for CPR, RBP, white blood cell distribution, or BCG scar prevalence. The results corroborate that OPV attenuates the immune response to co-administered BCG at birth.

19 November 2013 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
NKNicholas Kiraly
Nicholas Kiraly
ABAliu Balde
Aliu Balde
ILIda Marie Lisse
Ida Marie Lisse
HEHelle Brander Eriksen
Helle Brander Eriksen
PAPeter Aaby
Peter Aaby
CBChristine Stabell Benn
Christine Stabell Benn
The World Health Organization recommends high-dose vitamin A supplementation (VAS) for children above six months of age in low-income countries. VAS has been associated with up-regulation of the Th2 response. We aimed to determine if VAS is associated with atopy in childhood.

1 October 2014 in The Journal of Pediatrics
Verified
Journal Article
Closed access
HEHelle Brander Eriksen
Helle Brander Eriksen
SBSofie Biering-Sørensen
Sofie Biering-Sørensen
NLNajaaraq Lund
Najaaraq Lund
CCCizete Correia
Cizete Correia
ARAmabelia Rodrigues
Amabelia Rodrigues
CBChristine Stabell Benn
Christine Stabell Benn